CU20110219A7 - Composiciones y métodos para administración de vacunas contra virus del dengue - Google Patents

Composiciones y métodos para administración de vacunas contra virus del dengue

Info

Publication number
CU20110219A7
CU20110219A7 CU20110219A CU20110219A CU20110219A7 CU 20110219 A7 CU20110219 A7 CU 20110219A7 CU 20110219 A CU20110219 A CU 20110219A CU 20110219 A CU20110219 A CU 20110219A CU 20110219 A7 CU20110219 A7 CU 20110219A7
Authority
CU
Cuba
Prior art keywords
compositions
den
methods
intradermal
administration
Prior art date
Application number
CU20110219A
Other languages
English (en)
Inventor
Joseph N Brewoo
Charalambos D Partidos
Jorge E Osorio
Dan T Stinchcomb
Original Assignee
Inviragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43220488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110219(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inviragen Inc filed Critical Inviragen Inc
Publication of CU20110219A7 publication Critical patent/CU20110219A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención reporta composiciones y métodos para vacunar a un sujeto contra virus del dengue. En algunas modalidades, las composiciones de vacuna puden ser administradas por introducción intradérmica. En ciertas modalidades, la introducción intradérmica en un sujeto de una vacuna contra el virus de dengue puede incluir uno o más refuerzos intradérmicos después de la vacunación inicial. Otras modalidades incluyen la inyección intradérmica de una composición de vacuna contra el virus del dengue en donde la composición proporciona protección contra dos o más de DEN-1, DEN-2, DEN-3 y DEN-4.
CU20110219A 2009-06-01 2011-11-29 Composiciones y métodos para administración de vacunas contra virus del dengue CU20110219A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18302009P 2009-06-01 2009-06-01

Publications (1)

Publication Number Publication Date
CU20110219A7 true CU20110219A7 (es) 2012-06-21

Family

ID=43220488

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110219A CU20110219A7 (es) 2009-06-01 2011-11-29 Composiciones y métodos para administración de vacunas contra virus del dengue

Country Status (17)

Country Link
US (2) US9211323B2 (es)
EP (1) EP2438198A4 (es)
JP (2) JP5848243B2 (es)
KR (1) KR101876304B1 (es)
CN (2) CN102449172A (es)
AU (3) AU2010256845B2 (es)
CA (1) CA2763944A1 (es)
CL (1) CL2011003043A1 (es)
CO (1) CO6470882A2 (es)
CU (1) CU20110219A7 (es)
IL (2) IL216706A0 (es)
MX (1) MX343172B (es)
MY (1) MY184428A (es)
NZ (2) NZ618158A (es)
PH (1) PH12016502431A1 (es)
SG (1) SG176299A1 (es)
WO (1) WO2010141386A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188315A1 (en) * 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
CA3177574C (en) 2013-03-15 2026-03-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
JP2019511533A (ja) 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
CA3086456A1 (en) 2017-12-21 2019-06-27 Kirin Holdings Kabushiki Kaisha Cross-immunizing antigen vaccine and method for preparation thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11590221B2 (en) 2018-09-05 2023-02-28 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872553B1 (en) * 1991-09-19 2000-11-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimeric and/or growth-restricted flaviviruses
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
DK2278012T3 (en) 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
CA2755964C (en) 2001-05-22 2017-06-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
SG156666A1 (en) * 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US7618393B2 (en) * 2005-05-03 2009-11-17 Pharmajet, Inc. Needle-less injector and method of fluid delivery
DE602006015807D1 (de) * 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm
WO2007021672A2 (en) * 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
ZA200802176B (en) * 2005-08-10 2009-08-26 Acambis Inc Vaccination against dengue virus infection
DK2054428T3 (da) * 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法

Also Published As

Publication number Publication date
EP2438198A4 (en) 2014-05-14
CN107913406A (zh) 2018-04-17
CA2763944A1 (en) 2010-12-09
US9211323B2 (en) 2015-12-15
EP2438198A1 (en) 2012-04-11
KR101876304B1 (ko) 2018-07-10
AU2016277660A1 (en) 2017-01-12
US20160129102A1 (en) 2016-05-12
WO2010141386A1 (en) 2010-12-09
NZ597000A (en) 2014-07-25
IL243204A0 (en) 2016-02-29
KR20120027396A (ko) 2012-03-21
JP2012528794A (ja) 2012-11-15
CO6470882A2 (es) 2012-06-29
IL216706A0 (en) 2012-02-29
JP2016033151A (ja) 2016-03-10
NZ618158A (en) 2015-05-29
AU2010256845A1 (en) 2011-12-22
CL2011003043A1 (es) 2012-07-20
JP5848243B2 (ja) 2016-01-27
PH12016502431A1 (en) 2019-02-11
US10010600B2 (en) 2018-07-03
AU2010256845B2 (en) 2016-09-22
MY184428A (en) 2021-04-01
MX343172B (es) 2016-10-26
AU2019200212A1 (en) 2019-01-31
CN102449172A (zh) 2012-05-09
MX2011012807A (es) 2012-01-30
US20100303860A1 (en) 2010-12-02
SG176299A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
CO6470882A2 (es) Composiciones y metodos para administración de vacunas contra virus del dengue.
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
MX374519B (es) Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
EP2448410A4 (en) TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS
UY32457A (es) Vacuna del virus del dengue inactivado
PE20140646A1 (es) Vacuna de virus de dengue inactivado
BR112015001313A2 (pt) composições de vacina
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
MX383330B (es) Particula tipo virus de flavivirus.
UY32274A (es) Pestivirus quimericos
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
CO2017005830A2 (es) Composiciones de vacuna para el virus del dengue
WO2013012835A3 (en) Sirna useful in the treatment of flavivirus infection
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
AR082057A1 (es) Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (i)
TH91621A (th) วิธีการของการก่อภูมิคุ้มกันโรคเพื่อต่อต้าน 4 ซีโรไทป์ของไข้เลือดออก
TH91621B (th) วิธีการของการก่อภูมิคุ้มกันโรคเพื่อต่อต้าน 4 ซีโรไทป์ของไข้เลือดออก
TH137870A (th) องค์ประกอบและวิธีการสำหรับการให้ของวัคซีนต่อต้านไวรัสเดงกี่ (dengue virus)
NI201400025A (es) Inhibidores de aplicación viral
TH96612A (th) วิธีการให้ภูมิคุ้มกันต่อ 4 ซีไรไทป์ของไข้เดงกี